
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Monotherapy with tacrolimus 0.1 percent ointment (Protopic) is an effective and generally well-tolerated treatment for moderate to severe chronic red face, Wayne H. Fujita, M.D., said at the annual meeting of the American Academy of Dermatology.






